Fox Chase Cancer Center recently announced the awardees of the 2018 translational clinical protocol development based on basic and preclinical research results. Translational research disease groups were created with a multidisciplinary group of clinical and research-based faculty, with a focus on coordinating an ongoing assessment of translational research opportunities through investigator-initiated trials, interdisciplinary collaboration, research support, and trainee involvement. The program supports projects that are potentially paradigm-shifting; possess a high likelihood to lead to significant peer-reviewed funding; address community needs; and/or translate laboratory findings into new clinical treatments.
2018 Award Recipients
- Margaret von Mehren, MD, and Lori Rink, PhD, for their proposal, “Evaluation of Imatinib with ARQ092 Alone or in Combination with a PD-1 Inhibitor in Advanced Gastrointestinal Stromal Tumors”
- Joshua Meyer, MD, and Edna Cukierman, PhD, for their study, “Utilizing Pulsed Low-Dose–Rate Radiation to Prevent Radiation-Induced Stromal Activation: A Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial”
- Margie Clapper, PhD, and Michael Hall, MD, for their project, “Prevention of Colorectal Adenomas in Patients With Lynch Syndrome Using Atorvastatin and Aspirin: An Exploratory Biomarker Trial”
- Yanis Boumber, MD, PhD, and Suraj Peri, PhD, for their project, “Prospective Clinical Study of SCLC Patients With NSD1, NSD2 Mutations Receiving Platinum Doublet Chemotherapy.”
